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doi:10.1016/j.ejvs.2011.06.008Abstract Objectives: The Endurant Stent Graft System (Medtronic Vascular, Santa Rosa, CA)
is specifically designed to treat patients with abdominal aortic aneurysm, including those with
difficult anatomies. This is the 1-year report of a prospective, non-randomised, open-label trial
at 10 European centres.
Methods: Between November 2007 and August 2008, 80 patients were enrolled for elective en-
dovascular aneurysm repair (EVAR) with the Endurant; 71 with moderate (60) and nine with
high (60e75) infrarenal aortic neck angulation. Safety and stent-graft performance were as-
sessed throughout a 1-year follow-up period.
Results: The device was successfully delivered and deployed in all cases. All-cause mortality
was 5% (4/80), with one possibly device-related death. Serious adverse events were compa-
rable between the high and moderate angulation groups. There were no device migrations,
stent fractures, aortic ruptures or conversions to open repair. Maximal aneurysm diameter7031810; fax: þ31107032396.
usmc.nl (H.J.M. Verhagen).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
490 E.V. Rouwet et al.Table 1A Morphological inclusio
 Maximal aneurysm diameter 
 Maximal aneurysm diameter >
 Maximum aortic aneurysm dia
 Suprarenal aortic angulation 
with non-significant calcificat
OR
 Suprarenal aortic angulation 4
length 1.5 cm
Proximal AAA neck diameter 19
Distal iliac fixation site diameter
Distal non-aneurysmal iliac fixatiodecreased >5 mm in 42.7% of cases. A total of 28 endoleaks were observed (26 type II, two
undetermined). Three secondary endovascular procedures were performed for outflow vessel
stenosis, graft limb occlusion and iliac extension, resulting in a secondary patency rate of
100%. No re-interventions were required in the high angulation group.
Conclusions: The Endurant Stent Graft was successfully delivered and deployed in all cases and
performed safely and effectively in all patients, including those with unfavourable proximal
neck anatomy.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Endovascular abdominal aortic aneurysm repair (EVAR) has
played an increasingly important role in the management of
abdominal aortic aneurysm (AAA).1e4 Many studies have
confirmed the perioperative benefits of EVAR as compared
to open surgical repair.5e10
The evolution and diversification of stent graft and
delivery system designs have substantially improved the
application rate for (and outcomes with) EVAR,11,12 but
further development is needed in order to reduce compli-
cations and the need for re-interventions.13 Severe angu-
lations at the proximal aneurysm neck and small, calcified
and tortuous iliac access vessels are still recognised as
important risk factors that limit successful EVAR and are
associated with increased risks for secondary inter-
vention.14e18 As severe infrarenal aortic neck angulation
has been strongly associated with subsequent proximal type
I endoleak17 and graft migration,19 development of more
flexible devices has been identified as a design priority.20
Several strategies have been proposed for limiting compli-
cations related to arterial access,21,22 but the main factors
in facilitating safe device passage remain the diameter and
trackability of the delivery system.
The Endurant Stent Graft System (Medtronic Vascular,
Santa Rosa, CA, USA) is a next-generation evolution of the
Talent abdominal stent graft (Medtronic Vascular)23,24
designed to expand the applicability of EVAR. For access
through small tortuous iliac vessels, the profile of the
Endurant delivery system has been reduced. For improved
delivery into infrarenal angulation up to 75, the flexibility
of the suprarenal stent and the main body of the graft has
been markedly increased. Here, we report for the first
time the 1-year results of a prospective, non-randomised,
open-label trial of the Endurant Stent Graft System in 80
patients with both favourable and unfavourable proximal
neck angulation at 10 European Union (EU) centres. Then criteria consistent with Endu
5 cm
4 cm and <5 cm, with increas
meter 1.5 times reference ao
45 and infrarenal angulation
ion or thrombus
5e60 and infrarenal angulati
mm and 32 mm
8 mm and 25 mm
n length 15 mm bilaterally1-year results of the trial supported the Conformite´
Europe´ene (CE) marking for the Endurant in July 2008.Materials and Methods
Patient population: Between 14 November 2007 and 27
August 2008, 80 patients were enrolled for elective EVAR
with the Endurant Stent Graft System in a prospective, non-
randomised open-label trial at 10 EU centres. Patients were
18 years of age and were determined to be suitable
candidates for elective surgical repair of AAA, with preop-
erative risk assessed as American Society of Anaesthesiol-
ogists (ASA) class I, II or III. Pre-enrolment screening, within
30 days prior to implantation, included physical examina-
tion; computed tomographic angiography (CTA) of the
chest, abdomen and pelvis; and blood tests, including
serum creatinine measurement and complete blood count.
The morphological inclusion criteria consistent with the
Endurant instructions for use are detailed in Table 1A. All
preoperative CTAs were reviewed for eligibility and plan-
ning of EVAR using dedicated vascular imaging software
(3mensio Medical Imaging BV, Bilthoven, The Netherlands)
by an expert committee. Upon enrolment, patients were
stratified according to the degree of infrarenal angulation
of the aortic neck (the true angle between the longitudinal
axis of the proximal AAA neck and the longitudinal axis of
the AAA lumen25): angulation 60 versus angulation
60e75.
The exclusion criteria (Table 1B) included a conical
aneurysm neck (>2 mm distal increase over a 10-mm
length), circumferential aortic mural thrombus >2 mm
thick and/or significant calcification at the proximal or
distal attachment site and ectatic iliac arteries requiring
bilateral exclusion of hypogastric blood flow.rant instructions for use.
e 0.5 cm in past 6 months
rtic diameter
60 in combination with infrarenal AAA neck length 1 cm,
on 60e75 in combination with infrarenal AAA neck
Table 1B Exclusion criteria for participation in the trial.
Life expectancy 1 year, current participation in another trial, major surgical procedures planned within 30 days before or
after the Endurant stent implant
Aneurysms that were: thoracic, suprarenal, isolated ileofemoral, mycotic, inflammatory, symptomatic or acutely ruptured;
leaking AAA; or vascular injury due to trauma
History of bleeding diathesis or coagulopathy and those who refused blood transfusion
MI or CVA within the preceding 3 months
Known allergy or intolerance to the device components and those with known hypersensitivity or contraindication to
anticoagulants or contrast media not amenable to pretreatment
Creatinine >2.00 mg/dL or renal insufficiency not adequately managed by dialysis
AAA, abdominal aortic aneurysm; CVA, cardiovascular accident; MI, myocardial infarction.
European Endurant Stent-graft Trial 491The trial was conducted according to the Declaration of
Helsinki, with International Conference on Harmonisation
(ICH) Good Clinical Practice (GCP) guidance and approved
by local medical ethics committees.
Study device and procedure: The Endurant Stent Graft
(Fig. 1)25 consists of a multi-filament polyester graft
material that is externally supported by M-shaped stents to
provide conformability and flexibility. The proximal bare
stent design and anchoring pins allow secure and non-
occluding suprarenal fixation. The Endurant Stent Graft is
loaded into a flexible low-profile delivery system with
a hydrophilic coating for reduced friction and improved
trackability in access vessels and a deployment mechanism
with control-release tip capture of the suprarenal stent.
Available outer diameters are 18e20 F for the body
components and 14e16 F for the contralateral iliac limbs
and extension components.
The endovascular procedures were performed in hybrid
operating rooms under fluoroscopic control. General or
regional anaesthesia, antibiotic and heparin administration
and arterial access were employed according to each site’s
standard regimen. The stent-graft delivery system was
advanced with standard endovascular techniques and was
deployed according to user instructions. A final run-off
angiography was performed to document the status of the
device deployment, the aneurysm sac and the surrounding
vasculature.
Imaging and follow-up: At 30 days (2 weeks) and
12 months (8 weeks) after the procedure, CTA and
bi-directional plain abdominal X-ray were reviewed for
stent-graft position, patency and configuration, changes inFigure 1 The Endurant Stent Graft System (with view of supaneurysm size and presence of endoleak by an independent
core lab (M2S, Inc; Medical Data and Imaging Systems, West
Lebanon, NH, USA).
End points and definitions: The trial was designed to
assess clinical safety and performance of the Endurant graft
for the first year following implantation. The primary safety
end point was clinical success, defined as ‘30-day freedom
from all-cause mortality.’ Related safety analyses included
mortality through 1 year (crude rates and KaplaneMeier
estimates), assessment of mortality by adjudication of
cause and adverse events (including endoleaks) and serious
adverse events classified as device related, procedure
related and disease related. The primary effectiveness end
points were delivery success and deployment success.
Delivery success at the time of the index procedure was
defined as ‘successful vessel access and delivery of the
device to the intended anatomical treatment site’.
Deployment success was defined as ‘successful deployment
of the device in the intended site and successful removal of
the delivery system’. The secondary effectiveness end
point of technical success was defined as ‘30-day freedom’
from: type I/III endoleak; loss of device integrity; graft
infection, occlusion (defined as 100% obstruction) or
thrombosis (defined by the presence of clot(s) in the stent
graft, either occlusion or stenosis); primary or secondary
conversion to open surgical aneurysm repair; aneurysm
rupture; and secondary endovascular intervention involving
the targeted vascular segment with either manipulation of
the implanted Endurant Stent Graft or implantation of any
additional stent-graft devices. The components of the
technical success end point were further evaluatedrarenal anchoring pins) and the Endurant delivery system.
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rysm expansion (>5 mm), stent-graft migration (10 mm)
and stent-graft patency between 30 days and 1 year.
Data management and statistical analysis: Study
monitoring was performed by Medtronic CardioVascular
(Maastricht, The Netherlands). Database design, data
management and data analysis were the responsibility of
Cardialysis (Rotterdam, The Netherlands), an independent
contract research organisation. All protocol deviations,
procedural technical observations and reported adverse
events were reviewed by the study’s clinical events
committee (CEC) consisting of three independent members
(two vascular surgeons and one epidemiologist) who had no
investigative role in the trial. The sample size of 80 patients
was chosen based on the 1-year data requirements of
certain regulatory authorities. Patients in the two distinct
infrarenal angulation arms were analysed both separately
and pooled together. Study parameters and outcomes are
reported descriptively.
Results
From informed consent through follow-up, there were
minor protocol deviations, but these did not affect subject
welfare or the scientific validity of the data or conclusions
(tests done outside proposed time frame).
All 80 patients underwent implantation of the Endurant
Stent Graft and the designated periprocedural imaging.
Baseline patient and aneurysm characteristics: The
subject population was predominantly male, elderly and
ASA class II or III, with a high prevalence of cardiovascular
risk factors and co-morbidities (Table 2). Baseline aneurysm
characteristics are detailed in Table 3. Of the 80 patients,
71 had infrarenal angulation 60 and nine had infrarenal
angulation 60e75 with suprarenal neck angulation of
45e60.
Procedural details and delivery/deployment results:
The 80 subjects who underwent Endurant stent-graftTable 2 Demographics and risk factors.
Parameter Infrarenal angulation 6
Mean age  SD (years) (range) 72.0  7.18 (51e87)
Male gender 97.2% (69/71)
ASA class I 11.3% (8/71)
ASA class II 56.3% (40/71)
ASA class III 32.4% (23/71)
Arrhythmia 14.1% (10/71)
Coronary artery disease 32.4% (23/71)
Angina pectoris 15.5% (11/71)
Myocardial infarction 31.0% (22/71)
Congestive heart failure 1.4% (1/71)
Cerebrovascular accident 8.5% (6/71)
Peripheral arterial disease 4.2% (3/71)
COPD 14.1% (10/71)
Diabetes 21.1% (15/71)
Hypertension 77.1% (54/71)
Renal insufficiency 0.0% (0/71)
Tobacco use 56.3% (40/71)
ASA, American Society of Anaesthesiologists; COPD, chronic obstructiimplantation received a total of 242 device components
overall (Table 4). Specific technical observations included
difficulties withdrawing the sheath (nZ 2) or retracting the
nose cone (nZ 5), which were uneventfully resolved during
the index procedure. Overall, there was no decline in renal
function during follow-up, as assessed by serum creatinine
levels of 93  25.8 mmol l1 (range 47e182) at baseline,
94  27.3 mmol l1 (53e232) at 1 month, and
99  27.5 mmol l1 (53e219) at 1-year follow-up.
Stent-graft performance: There were no type I or type
III endoleaks identified by the core laboratory and there
was no loss of device integrity, conversion to open surgical
repair, aneurysm rupture, stent-graft migration or graft
infection through 1 year (Table 5). The 1-year primary
patency rate was 98.6%. One patient with complete
occlusion of a graft limb was successfully treated by re-
canalisation and stent placement, resulting in a 100% 1-
year secondary patency rate. Three grafts showed a small
rim of mural thrombus, none being haemodynamically
significant or symptomatic.
Overall, 28 endoleaks were identified: 26 were deter-
mined as type II and two could not be specified due to poor
CTA quality. The mean change in aneurysm sac diameter at
12-month follow-up was 6.1  7.4 mm (range 33 to
þ15 mm). Maximal aneurysm diameter decreased >5 mm in
42.7% (32/75) with a median decrease of 11.0 mm. Maximal
aneurysm diameter increased >5 mm in two patients with
moderate neck angulation with type II endoleaks from the
inferior mesenteric and lumbar arteries; both were
managed conservatively without clinical sequelae.
Overall, three patients (3.8%) required a secondary
stent-graft-related endovascular procedure during the first
year after EVAR, all of these occurring among patients with
infrarenal angulation 60; one aforementioned patient
with graft occlusion, one patient underwent a PTA of the
external iliac artery distal to the stent graft and one
patient underwent an endograft extension to lengthen the
distal sealing zone.0 (n Z 71) Infrarenal angulation 60e75 (n Z 9)
79.3  6.41 (67e88)
77.8% (7/9)
0.0% (0/9)
55.5% (5/9)
44.4% (4/9)
44.4% (4/9)
55.5% (5/9)
33.3% (3/9)
55.6% (5/9)
0.0% (0/9)
11.1% (1/9)
0.0% (0/9)
33.3% (3/9)
11.1% (1/9)
77.8% (7/9)
11.1% (1/9)
55.6% (5/9)
ve pulmonary disease.
Table 3 Baseline aneurysm characteristics.
Parameter Infrarenal angulation 60 (n Z 71) Infrarenal angulation 60e75 (n Z 9)
Maximal AAA diameter (mm) 55.9  5.73 (43e74) 64.2  7.82 (57e82)
Proximal neck diameter (mm) 24.2  2.87 (17e30) 26.2  2.73 (23e31)
Proximal neck length (mm) 26.8  11.74 (10e73) 31.9  18.58 (13e70)
AAA length (mm) 119.1  14.26 (93e158) 136.1  22.45 (100e168)
Suprarenal aortic angulation
45 100% (71/71) 0% (0/9)
45e60 0% (0/71) 100% (9/9)
AAA, abdominal aortic aneurysm.
Data are presented as mean  SD (range) or percentage.
European Endurant Stent-graft Trial 493Patient outcome: The primary safety end point, defined
as ‘freedom from all-cause mortality within 30 days’, was
97.5% (78/80; 95% confidence interval (CI) 91.4e99.7%).
Through the 12 months of follow-up, the all-cause mortality
rate was 5.0% (4/80). The KaplaneMeier estimates of
freedom from all-cause mortality were 97.5%  1.72% and
95.0%  2.44%, at 1 month and 1 year postoperatively,
respectively (Fig. 2).Table 4 Procedural details.
Parameter Infrarenal angulation
Delivery successa 100% (71/71)
Deployment successb 100% (71/71)
Contrast used (n) 62
Contrast volume (mL) 115.0  63.78 (30e41
Contrast usage unknown (n) 9
Anaesthesia
Regional 36.6% (26/71)
Local 2.8% (2/71)
General 60.6% (43/71)
Blood transfusion required 1.4% (1/71)
Time in intensive care unit (hours) 6.0  10.00 (0e37)
Overall hospital stay (days) 6.5  2.78 (3e20)
Data are presented as mean  SD (range) or percentage.
a Successful vascular access and delivery of the device to the inten
b Successful deployment of the device in the intended site and the
0e30
days
1e6
months
6e12
months
Number entereda 80 76 76
Number of events 2 0 2
Number censoredb 2 0 21
Number at riskc 76 76 53
KaplaneMeier estimate 97.5% 97.5% 95.0%
Greenwood SE 1.72% 1.72% 2.44%
SE, standard error.
a Number of subjects at risk at the beginning of the interval.
b Subjects were censored if their last follow-up had not
reached the end of the time interval or because they were lost
to follow-up.
c Number at risk at the end of the interval [ number
entered  number censored  number of events.Two deaths occurred within 30 days, both in the group with
infrarenal angulation 60, one due to fatal gastrointes-
tinal bleeding and the other due to unknown causes,
possibly pulmonary embolism. Two additional deaths
occurred in the 30-day to 1-year follow-up period due to
cancer and massive gastrointestinal bleeding. Two of these
deaths were classified by the clinical event committee as
‘disease related’ and one also as ‘possibly device-related’
(occlusion of crural vessels at re-admittance, treated with
heparin infusion leading to massive GI-bleed. No stent-graft
abnormalities at autopsy). The other two deaths were
classified as not being procedure-, device-, or disease-
related events.
In terms of serious adverse events (Table 6), there were
no differences between patients with high infrarenal
angulation and those with moderate infrarenal angulation.
Three of the 80 Endurant implantations were complicated
by a groin haematoma requiring a secondary intervention.
One patient developed a severe wound infection, requiring
operative drainage.
Two cases of access artery stenosis were reported, one
resulting in intermittent claudication from dissection of the
left iliac artery, treated by angioplasty and stenting. The
other patient developed acute lower limb ischaemia, which
was resolved by patch angioplasty of the common femoral
artery. Arterial thrombo-embolic events were reported for
three patients with no evidence of an embolic origin in the60 (n Z 71) Infrarenal angulation 60e75 (n Z 9)
100% (9/9)
100% (9/9)
8
0) 103.1  29.99 (50e140)
1
44.4% (4/9)
0% (0/9)
55.6% (5/9)
33.3% (3/9)
12.0  21.46 (0e63)
11.2  6.30 (5e23)
ded anatomical treatment site.
successful removal of the delivery system.
Table 5 Secondary endpoints.
Device-related complications 0 through 30 days 0 through 12 months
All patientsa All patientsa
Type I/III endoleaks 0% (0/79) 0% (0/77)
Loss of device integrity 0% (0/48) 0% (0/62)
Graft stenosis 0% (0/68) 0% (0/79)
Graft kinking 0% (0/22) 3.4% (2/59)
Graft thrombosis 1.3% (1/79) 4.0% (3/75)
Graft occlusion (complete thrombosis) 0% (0/79) 1.3% (1/75)
Conversion to open surgeryb 0% (0/80) 0% (0/80)
Aneurysm ruptureb 0% (0/80) 0% (0/80)
Secondary endovascular procedureb 0% (0/80) 3.8% (3/80)
Graft infectionb 0% (0/79) 0% (0/75)
Aneurysm expansion >5 mmc 2.7% (2/75)
Stent-graft migration 10 mmc 0% (0/75)
Primary stent-graft patencyc 98.6% (73/74)
a Patients were excluded from the denominator on a per end point basis when the outcome was scored as unknown or when no status
was scored before the occurrence of death.
b Physician reported end point, not adjudicated by core lab.
c Outcome tracked between 0 days and 12 months.
494 E.V. Rouwet et al.Endurant Stent Graft. One patient presented with
a ruptured popliteal artery aneurysm that was treated by
surgical reconstruction.
Within the first year following EVAR, seven patients
received additional interventions which were related
neither to the AAA nor to the EVAR procedure: laparoscopic
adhesiolysis (n Z 1), cardiac intervention (n Z 3), bowel
surgery (n Z 1), lymph node biopsy (n Z 1) and inguinal
hernia repair (n Z 1).
Discussion
The Endurant EU multicentre clinical study was designed to
assess the clinical safety and performance of the next-
generation Endurant Stent Graft System for the elective
endovascular treatment of AAA. The primary safety end
point of clinical success, defined as ‘freedom from all-causeFigure 2 The KaplaneMeier estimate of freedom from all-
cause mortality was 97.5%  1.72% at 30 days, also
97.5%  1.72% for the period from 30 days through 6 months,
and 95.0%  2.44% for the period from 6 months through 12
months.mortality’, was achieved in 95% of patients at 1 year after
EVAR. The safety profile of this new device seems good,
both for moderately- and for highly-angulated infrarenal
aortic necks.
In spite of the benefits of EVAR over conventional open
surgical AAA repair, unfavourable anatomy, until now,
precluded the use of EVAR for AAA treatment in 30e60% of
patients.15,16,26 The various periprocedural and late
complications associated with EVAR in the context of
hostile neck anatomy25,27,28 include the inability to achieve
adequate sealing to the aortic wall, resulting in unfav-
ourable outcomes.17,19,29e31
Appropriate device selection for EVAR depends on careful
consideration of the interplay of specific device features
with patient anatomy and physical status.11,32,33 The degree
of columnar strength affects the ability to conform to
tortuous anatomies. Longer and stiffer stents make accom-
modation of angulated proximal implantation zones more
challenging andmay contribute to proximal-attachment-site
endoleaks or graft kinking when deployment occurs in
tortuous vessels.34,35 Deployment of flexible and conform-
able stent grafts with proximal anchoring pins seems espe-
cially desirable for patients with more angulated necks and
tortuous anatomies.11,20,31 Among next-generation stent-
graft designs evolving to address the issues that affect
further expansion of EVAR applicability, the Aorfix (Lombard
Medical, Didcot, UK) and the Anaconda device (Vascutek,
Terumo, Renfrewshire, Scotland) have been studied, but
usually with a higher rate of type I endoleak.20,36,37
All implantation procedures of the Endurant Stent Graft
were successful in terms of delivery to the infrarenal target
site and deployment in a range of abdominal aortic anato-
mies. Throughout the 1-year follow-up period, therewere no
(1) type I or III endoleaks, (2) graft migration or (3) AAA
rupture, and only two patients with increases in aneurysm
sac diameter>5mm due to type II endoleaks. There was one
report of graft limb occlusion that required re-intervention
to restore patency, resulting in a 100% 1-year secondary
patency rate. Overall, only three patients (3.8%) required
Table 6 Serious adverse events.
Serious adverse eventsa 0e30 days 0e12 months
All patientsb Infrarenal angulation
60b
Infrarenal angulation
60 to 75b
All patientsb
Pulmonary complications 3.8% (3/80) 4.2% (3/71) 0% (0/9) 3.8% (3/80)
Cardiac events 1.3% (1/80) 4.2% (3/71) 11.1% (1/9) 5.0% (4/80)
Congestive heart failure 0% (0/80) 1.4% (1/71) 0% (0/9) 1.3% (1/80)
Cardiac arrhythmia 1.3% (1/80) 1.4% (1/71) 0% (0/9) 1.3% (1/80)
Myocardial infarction 0% (0/80) 1.4% (1/71) 11.1% (1/9) 2.5% (2/80)
General cardiac/hemodynamic 0% (0/80) 1.4% (1/71) 11.1% (1/9) 2.5% (2/80)
Neurological events 1.3% (1/80) 2.8% (2/71) 0% (0/9) 2.5% (2/80)
Stroke 1.3% (1/80) 1.4% (1/71) 0% (0/9) 1.3% (1/80)
General neurologic 0% (0/80) 1.4% (1/71) 0% (0/9) 1.3% (1/80)
Gastrointestinal events 2.5% (2/80) 2.8% (2/71) 11.1% (1/9) 3.8% (3/80)
Bowel obstruction 1.3% (1/80) 1.4% (1/71) 0% (0/9) 1.3% (1/80)
General gastrointestinal 2.5% (2/80) 2.8% (2/71) 11.1% (1/9) 3.8% (3/80)
Bleeding events 8.8% (7/80) 5.6% (4/71) 44.4% (4/9) 10.0% (8/80)
Haematoma 6.3% (5/80) 4.2% (3/71) 22.2% (2/9) 6.3% (5/80)
Gastrointestinal bleeding 2.5% (2/80) 1.4% (1/71) 22.2% (2/9) 3.8% (3/80)
Vascular events 5.0% (4/80) 9.9% (7/71) 11.1% (1/9) 10.0% (8/80)
Arterial stenosis 1.3% (1/80) 1.4% (1/71) 11.1% (1/9) 2.5% (2/80)
Arterial thromboembolism 1.3% (1/80) 4.2% (3/71) 0% (0/9) 3.8% (3/80)
Other arterial complications 0% (0/80) 1.4% (1/71) 0% (0/9) 1.3% (1/80)
Venous 1.3% (1/80) 1.4% (1/71) 0% (0/9) 1.3% (1/80)
Other 2.5% (2/80) 9.9% (7/71) 11.1% (1/9) 10.0% (8/80)
Cancer 1.3% (1/80) 4.1% (3/71) 0% (0/9) 3.8% (3/80)
Edema 1.3% (1/80) 1.4% (1/71) 0% (0/9) 1.3% (1/80)
Wound infection 0% (0/80) 1.4% (1/71) 0% (0/9) 1.3% (1/80)
Other 1.3% (1/80) 2.8% (2/71) 11.1% (1/9) 3.8% (3/80)
Subjects may experience one or more adverse events but are counted only once for each (sub)category and time period.
a All reported adverse events classified by the clinical events committee as definitely related or possibly/probably related to the AAA
per adverse-event category and subcategory with a summary of any disease-related adverse event.
b mZ number of subjects in the category, nZ number of subjects evaluable at the beginning of the interval, and percentage (%) was
calculated as 100  (m/n).
European Endurant Stent-graft Trial 495a secondary stent-graft-related endovascular procedure
during the first year after EVAR and there were no conver-
sions to open surgery. Importantly, there were no device-
related complications in patients with high infrarenal aortic
neck angulation.
This multicentre trial experience confirms our previous
preliminary estimation.38,39 With use of the top stent release
mechanism, readjustment of graft positioning during
deployment is facilitated. The four markers at the top of the
graft fabric can be lined up to accomplish repositioning of
the image intensifier in the cranialecaudal plane and ensure
that a perpendicular view of the aorta is achieved and that
the maximum available length of neck is covered by the
graft. With proper preparation, this intuitive deployment
system may well enable users to expand the application of
EVAR safely and without a lengthy learning curve. This trial
also indicates that good results may be achieved in cases
with highly-angulated necks, confirming recently described
short-term results.40 Larger series with prolonged follow-up
will be required to validate these results.
In conclusion, this is the first report on the 1-year results
of a prospective multicentre trial using the Endurant
next-generation stent graft for elective endovascular repair
of infrarenal AAA. The 1-year results are favourable, even
in patients with high infrarenal aortic neck angulation,exceeding indications for the preceding generation of
devices.
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